The National Institutes of Health and its role in creating U.S. high-technology industry growth and jobs: hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, first session, Washington, DC, December 9, 1991
What people are saying - Write a review
We haven't found any reviews in the usual places.
Monday December 9
Moskowitz Jay Associate Director for Science Policy and Legislation NIH
Adler Reid G letter in response to Chairman Wydens questions during
Adler agency Alzheimer's disease American annual applied research base basic research BERNADINE HEALY biology biomedical research enterprise biomedicine biotechnology breast cancer Bristol-Myers Squibb Chair Chairman Wyden cisplatin clinical trials competition components concerns contraceptive contraceptive research cooperative research cost of treatment CRADA Director discoveries drug economic ensure estimated example Federal funds future gene therapy genetic goals going Health Care Advance Healy human genome identified improve health innovation Institutes of Health intramural investment issues kidney stones laboratories leadership look major ment million molecular medicine Moskowitz National Institutes NIH Strategic Plan NIH-supported research NIH's Office of Technology opportunities Patent Office percent pharmaceutical potassium citrate potential prevent private sector question reasonable pricing clause Reduces cost research and development RON WYDEN Science Policy scientific scientists Small Business specific Subcommittee on Regulation taxol technology transfer therapeutic treatment costs vaccine women